CSL Behring Deal History & Licensing Activity
CSL Behring is a large biotech headquartered in Australia. Over the past three years, CSL Behring has been involved in 6 licensing and acquisition transactions, with a primary focus on Antibodies (6 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
Antibodies
Focus Area
Rare Disease
CSL Behring Recent Deal Activity
Licensing, acquisition, and partnership transactions involving CSL Behring in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| etranacogene dezaparvovec | uniQure | Gene Therapy | Approved | license | Apr 2026 |
| etranacogene dezaparvovec (Hemgenix) | uniQure | Gene Therapy | Approved | license | Apr 2026 |
| clazakizumab | Eli Lilly | Antibodies | Phase 3 | license | Feb 2026 |
CSL Behring Pipeline Focus
Therapeutic areas and modalities where CSL Behring is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
CSL Behring Strategic Signals
Key indicators of CSL Behring's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches CSL Behring's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Rare Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Cardiovascular Deal Benchmarks
Market sizing, deal terms, and competitive landscape for cardiovascular
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About CSL Behring Licensing & Deal Activity
CSL Behring is a large biotech company based in Australia that has been actively engaged in licensing transactions across the biopharma landscape. With 6 deals over the past three years, CSL Behring ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for CSL Behring include Rare Disease (5 deals and trials), Cardiovascular (4 deals and trials), and Other (2 deals and trials). In terms of modality, CSL Behring has shown particular interest in antibodies, gene therapy.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for CSL Behring and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against CSL Behring's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.